全球癌症免疫治疗市场规模（按治疗类型、应用、最终用户、地区、范围和预测）

癌症免疫治疗市场规模及预测

癌症免疫治疗市场规模预计在2024年达到1216.9亿美元，预计在2024年至2031年期间将以13.70%的复合年增长率增长，到2031年将达到3104.5亿美元。达到1.癌症免疫疗法是一种利用人体天然防御系统—免疫系统的新型癌症治疗方法。与化疗和放射疗法等直接针对和摧毁癌细胞的传统技术不同，免疫疗法利用免疫系统来识别和消灭癌细胞。免疫疗法激活免疫系统，使其更积极地对抗癌症，使免疫细胞更好地识别和靶向恶性细胞，并提高免疫系统攻击癌症的能力。这种独特的治疗理念显示出提供更有针对性、危害更小的癌症治疗方法的潜力。

全球各种恶性肿瘤发生率的上升正在推动全球免疫肿瘤学市场的成长。癌症发生率的上升是推动新的有效治疗技术的需求的一个主要因素。癌症是全世界发病和死亡的主要原因，包括肺癌、乳癌、大肠癌、黑色素瘤和血液系统恶性肿瘤等多种病症，需要开发新的治疗方法。这种情况凸显了发现巧妙的技术来对抗日益加重的全球癌症负担的重要性。

癌症治疗的一个显着变化是越来越重视联合疗法，这是一种提高疗效和扩大覆盖范围的有力途径。这种方法探索了结合多种免疫疗法或将免疫疗法与常规治疗相结合的协同技术的发展。这些组合的基本前提是利用每种治疗策略的特定能力，从而对癌细胞进行更全面、更精确的标靶攻击。这些药物的计画组合旨在增强人体的免疫反应，克服潜在的抗药性机制，并改善整体癌症治疗效果。

全球癌症免疫治疗市场动态

主要市场驱动因子

癌症发生率上升：

全球癌症发生率的增加是癌症免疫治疗市场的主要驱动力。随着越来越多的人被诊断出患有各种类型的癌症，对有效治疗的需求也越来越大。免疫疗法利用人体免疫系统对抗癌症，作为一种可能的治疗方法正越来越受欢迎。

生物技术的进步：

生物技术和基因工程的不断进步正在加速创新免疫疗法的发现。 CAR-T 细胞疗法和检查点抑制剂正在彻底改变癌症治疗。这些发展正在推动更有针对性、更有效率和个人化的治疗方法的发展，从而推动市场成长。

增加研发：

製药公司和学术机构正在大力投资研发，以加速推出新型免疫疗法药物。临床研究和合作研究计画正在推进我们对免疫疗法的理解和应用。新型疗法的涌入将有助于扩大市场并为患者提供新的选择。

有利的监理环境：

世界各地的监管机构正在为创新癌症免疫疗法的批准创建更有利的框架。加快审批流程、孤儿药及突破性疗法认定可加快进入市场的速度。这种支持性的监管环境有利于促进创新并加速向患者提供新治疗方法。

主要问题

成本高、易用性差

癌症免疫治疗业务的最大问题之一是治疗费用高昂。这些治疗通常很昂贵，因为它们涉及先进的技术和个人化的方法。高昂的费用可能会限制人们获得医疗服务的机会，特别是在医疗资源有限且保险覆盖率较差的中低收入国家。

治疗的复杂性：

癌症免疫疗法非常复杂，需要专门的医疗技术和基础设施。这些治疗课题通常需要复杂的程序和监测，而欠发达的医疗保健系统很难解决。此外，一些免疫疗法是针对每个患者量身定制的，这意味着传统的治疗方案可能并不总是合适的。

副作用与安全性问题

癌症免疫疗法已显示出良好的效果，但并非没有风险。患者可能会出现严重的副作用，包括自体免疫反应，即免疫系统攻击健康组织。这些副作用的处理需要密切的监测和监督，这可能很困难并可能限制这些药物的广泛使用。

监理与审批障碍：

癌症免疫疗法面临严格的监管要求，包括大规模临床试验和安全性和有效性的证明。获得监管部门的批准既费时又昂贵。此外，不同地区不同的监管要求可能会阻碍创新免疫疗法的全球采用和应用。

主要趋势

正在使用的检查点抑制剂：

检查点抑制剂的使用日益增多是癌症免疫治疗业务的一个主要趋势。这些药物包括派姆单抗和纳武单抗，可提高免疫系统识别和对抗癌细胞的能力。它对多种恶性肿瘤（包括黑色素瘤和肺癌）的疗效使其成为免疫疗法的基石。

个人化癌症疫苗：

另一个主要趋势是开发个人化癌症疫苗。这些疫苗根据个人肿瘤的基因组成进行个人化接种，使免疫系统能够更有效地瞄准和消灭癌细胞。基因组学和生物技术的进步推动了这种个人化方法的发展，有望实现更有效、更有针对性的治疗。

CAR-T细胞疗法的发展：

嵌合抗原受体 T 细胞（CAR-T）疗法作为一种有前景的癌症治疗方法而广受欢迎。 CAR-T疗法是一种改变患者T淋巴细胞的治疗方法，使其能够更好地识别和杀死癌细胞。最近的进展提高了CAR-T疗法的疗效和安全性，使其能够用于更广泛的癌症类型，从而得到更广泛的应用。

合併治疗：

免疫疗法通常与其他治疗方法结合，例如化疗、放射疗法和标靶疗法。此种联合疗法旨在透过多种机制治疗癌症，提高整体治疗效果。临床试验和研究不断探索最佳联合疗法，以改善患者的治疗效果并提高存活率。

目录

第 1 章简介

• 市场定义
• 市场区隔
• 研究方法

第 2 章执行摘要

• 主要发现 市场概况
• 市场亮点

第3章 市场概览

• 市场规模与成长潜力
• 市场趋势
• 市场推动因素
• 市场限制
• 市场机会
• 波特五力分析

第4章 癌症免疫治疗市场（依治疗类型）

• 单株抗体
• 检查点抑制剂
• 抗癌疫苗
• 过继细胞转移
• 其他

第5章 癌症免疫治疗市场（依应用）

• 实体肿瘤
• 血液系统恶性肿瘤

第6章 癌症免疫治疗市场（依最终使用者）

• 医院和诊所
• 癌症研究所
• 门诊手术中心

第 7 章 区域分析

• 北美洲
• 美国
• 加拿大
• 墨西哥
• 欧洲
• 英国
• 德国
• 法国
• 义大利 亚太地区
• 中国
• 日本
• 印度
• 澳大利亚
• 拉丁美洲
• 巴西
• 阿根廷
• 智利
• 中东和非洲
• 南非
• 沙乌地阿拉伯
• 阿拉伯联合大公国

第 8 章 市场动态

• 市场推动因素
• 市场限制
• 市场机会
• COVID-19 市场影响

第 9 章 竞争格局

• 大型公司
• 市占率分析

第10章 公司简介

• Amgen（U.S.）
• AstraZeneca（U.K.）
• F. Hoffmann-La Roche（Switzerland）
• Bayer AG（Germany）
• Bristol-Myers Squibb（U.S.）
• Eli Lilly and Company（U.S.）
• Janssen Global Services, LLC（Belgium）
• Merck（U.S.）
• Novartis（Switzerland）
• Pfizer（U.S.）

第 11 章 市场展望与机会

• 新兴技术
• 未来市场趋势
• 投资机会

第 12 章附录

• 缩写列表
• 来源与参考文献

Cancer Immunotherapy Market Size And Forecast

Cancer Immunotherapy Market size was valued at USD 121.69 Billion in 2024 and is projected to reach USD 310.45 Billion by 2031 , growing at a CAGR of 13.70% from 2024 to 2031. Cancer immunotherapy is a novel method of cancer treatment that takes advantage of the body's natural defensive system, the immune system. Unlike conventional techniques such as chemotherapy or radiation, which directly target and destroy cancer cells, immunotherapy allows the immune system to recognize and eradicate them. It accomplishes this through a variety of processes, including boosting the immune system to become more aggressive against cancer, preparing immune cells to better recognize and target malignant cells, and eliminating obstructions that impede the immune system from attacking cancer. This unique therapeutic concept shows promise for providing a more tailored and potentially less harmful approach to cancer treatment.

The rising global incidence of various malignancies is driving the global cancer immunotherapy market's growth. The rise in cancer prevalence is a major factor driving the demand for novel and effective treatment techniques. Cancer remains a leading cause of morbidity and mortality worldwide, with numerous forms including lung, breast, colorectal, melanoma, and hematological malignancies, necessitating the development of novel treatments. This situation emphasizes the importance of discovering creative techniques to combat the expanding worldwide cancer burden.

A noticeable shift in cancer treatment is the growing emphasis on combination medicines, which provide a compelling pathway for increased effectiveness and broader applicability. This approach entails investigating the development of synergistic techniques that combine several immunotherapies or integrate immunotherapy with traditional treatments. The essential premise of these combinations is to leverage on the specific capabilities of each therapy strategy, resulting in a more comprehensive and precisely targeted attack on cancer cells. The planned combination of these medicines is intended to boost the body's immunological response, overcome potential resistance mechanisms, and improve overall cancer therapy outcomes.

Global Cancer Immunotherapy Market Dynamics

The key market dynamics that are shaping the global cancer immunotherapy market include:

Key Market Drivers:

Increasing Cancer Prevalence:

The rising global prevalence of cancer is a major driver of the cancer immunotherapy market. As more people are diagnosed with various types of cancer, there is an increased demand for effective therapies. Immunotherapy, which uses the body's immune system to fight cancer, is gaining popularity as a possible treatment.

Biotechnology Advancements:

Continuous advances in biotechnology and genetic engineering are accelerating the discovery of innovative immunotherapies. CAR-T cell therapy and checkpoint inhibitors are transforming cancer treatment. These developments lead to more targeted, efficient, and individualized therapeutic alternatives, which boosts market growth.

Increased academic and Development:

Pharmaceutical companies and academic institutions are making significant investments in R&D to accelerate the introduction of novel immunotherapy medications. Clinical studies and collaborative research projects are advancing our understanding and application of immunotherapy. This inflow of novel treatments promotes market expansion and gives patients additional options.

Favorable Regulatory Environment:

Regulatory authorities around the world are developing more favorable frameworks for the approval of innovative cancer immunotherapy treatments. Accelerated approval processes and specific designations, such as orphan drug status and breakthrough therapy designations, allow for speedier market access. This supportive regulatory environment promotes innovation and accelerates the availability of novel treatments to patients.

Key Challenges:

High Costs and Accessibility:

One of the most significant problems in the cancer immunotherapy business is the high cost of treatment. These therapies are generally pricey because to the use of advanced technology and individualized approaches. This high cost can limit access, especially in low- and middle-income countries where healthcare resources are limited and insurance coverage may be insufficient.

Complexity of Treatment:

Cancer immunotherapy can be complicated, necessitating specific medical skills and infrastructure. Administering these therapies frequently requires complicated procedures and monitoring, which can be challenging to handle in underdeveloped healthcare systems. Furthermore, because some immunotherapies are customized, traditional treatment regimens may not always be suitable.

Side Effects and Safety Concerns:

Although cancer immunotherapy has produced promising outcomes, it is not without hazards. Patients may encounter severe adverse effects, including as autoimmune responses, in which the immune system assaults healthy tissues. Managing these side effects necessitates close monitoring and management, which can be difficult and may limit the broad use of these medicines.

Regulatory and approval hurdles:

Cancer immunotherapies face strict regulatory requirements, including significant clinical trials and evidence of safety and efficacy. Obtaining regulatory approval can be a lengthy and expensive procedure. Furthermore, differences in regulatory requirements across areas can impede the global dissemination and uptake of innovative immunotherapy treatments.

Key Trends:

Checkpoint Inhibitor Adoption:

The increased use of checkpoint inhibitors is an important trend in the cancer immunotherapy business. These medications, including pembrolizumab and nivolumab, improve the immune system's ability to recognize and fight cancer cells. Their efficacy in treating a variety of malignancies, including melanoma and lung cancer, has established them as a cornerstone of immunotherapy.

Personalized Cancer Vaccinations:

Another major trend is the creation of personalized cancer vaccinations. These vaccinations are personalized to an individual's tumor's genetic makeup, allowing the immune system to target and eliminate cancer cells more effectively. Advances in genomics and biotechnology are propelling this tailored approach, which promises more effective and focused treatments.

CAR-T Cell Therapy Developments:

Chimeric Antigen Receptor T-cell (CAR-T) therapy is gaining popularity as a promising cancer treatment. This entails altering a patient's T lymphocytes to better recognize and kill cancer cells. Recent advances have enhanced the efficacy and safety of CAR-T treatments, allowing them to be used on a wider range of cancer types and boosting adoption.

Combination Therapies:

Immunotherapy is increasingly being used in conjunction with other treatments including as chemotherapy, radiation, and targeted therapies. These combined techniques seek to improve overall treatment efficacy by treating cancer via numerous mechanisms. Clinical trials and research are constantly looking for the optimum combinations to enhance patient outcomes and increase survival rates.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Cancer Immunotherapy Market Regional Analysis

Here is a more detailed regional analysis of the global cancer immunotherapy market:

North America:

North America is the leading market for cancer immunotherapy due to its advanced healthcare infrastructure and significant expenditure in medical research. The region's finest hospitals and research institutions are pioneering the development and implementation of cutting-edge treatments. Furthermore, significant funding from both the public and corporate sectors promotes ongoing research and clinical studies in immunotherapy.

Another important consideration is the presence of large pharmaceutical and biotechnology businesses in North America. These firms are driving the industry by creating new immunotherapy medications and cooperating with research organizations. The concentration of these enterprises enables the speedy commercialization and widespread dissemination of novel medicines throughout the region.

Regulatory backing and attractive reimbursement rules bolster North America's cancer immunotherapy sector. The FDA and other agencies hasten the approval process for breakthrough therapies, ensuring that patients have timely access. Furthermore, insurance companies and government programs frequently cover the high expenses of these therapies, making them more affordable to a larger audience.

The increasing cancer prevalence in North America emphasizes the need for effective treatments such as immunotherapy. The population's awareness and proactive approach to obtaining modern medical treatments help to drive market growth. As patients and healthcare providers prioritize cutting-edge therapies, demand for cancer immunotherapy is projected to stay high.

Asia Pacific:

The Asia Pacific area is the fastest-growing market for cancer immunotherapy, owing to its huge and aging populations. Countries such as China and India have a large number of cancer patients, producing a strong demand for effective therapies. The rising frequency of cancer in these populated countries hastens the implementation of novel medicines, including immunotherapy, which gives promise for better patient outcomes.

Government initiatives and supporting healthcare policies both contribute to this tremendous expansion. Many Asia Pacific countries are investing considerably in healthcare infrastructure and R&D. These initiatives are intended to improve cancer treatment facilities and make innovative therapies more accessible to the public. Furthermore, regulatory frameworks are improving, enabling international pharmaceutical companies to expand their operations in the region.

Economic growth and increased disposable incomes in Asia Pacific are further propelling the industry. As the middle class grows, more people are able to purchase expensive medical procedures. This financial capability, combined with improved health awareness, drives growing demand for cutting-edge cancer treatments such as immunotherapy. Furthermore, the private healthcare sector is thriving, providing previously inaccessible cutting-edge treatments.

The Asia Pacific area is experiencing an increase in clinical trials and collaborations between local and multinational pharmaceutical businesses. This collaborative atmosphere promotes creativity and speeds up the development and approval of novel cancer immunotherapies. Local biotech enterprises are actively involved in worldwide research programs, expanding their knowledge and contributing to the region's rapid growth in the immunotherapy sector.

Global Cancer Immunotherapy Market: Segmentation Analysis

The Global Cancer Immunotherapy Market is Segmented on the basis of Therapy Type, Application, End-User, and Geography.

Cancer Immunotherapy Market, By Therapy Type

• Monoclonal Antibodies
• Checkpoint Inhibitors
• Vaccines against cancer
• Adoptive Cell Transfer

Based on Therapy Type, the market is bifurcated into monoclonal antibodies, checkpoint inhibitors, vaccines against cancer, and adoptive cell transfer. Checkpoint inhibitors presently dominate cancer immunotherapy market due to their proven efficacy in treating a variety of malignancies. This has resulted in widespread adoption and a steadily expanding market share. With continued research and development supporting the invention of increasingly better checkpoint inhibitors, their supremacy appears to be sustainable for the foreseeable future. However, monoclonal antibodies and new therapeutics such as cancer vaccines and adoptive cell transfer should not be overlooked because they show promise for future expansion.

Cancer Immunotherapy Market, By Application

• Solid Tumors
• Hematological Malignancies

Based on Application, the market is segmented into Solid Tumors and Hematological Malignancies. Solid tumors dominate the cancer immunotherapy industry because to their higher prevalence than hematological malignancies. Immunotherapies are being used to treat a variety of solid malignancies, including lung, breast, and colorectal cancers. Targeted treatments and checkpoint inhibitors have demonstrated great efficacy in treating these cancers. Furthermore, their market domination stems from considerable research and multiple clinical studies focusing on solid tumors. The wider patient pool and better outcomes in treating solid tumors help to maintain their market leadership.

Cancer Immunotherapy Market, By End-User

• Hospitals and Clinics
• Cancer Research Institutes
• Ambulatory Surgical Centers

Based on, End-User the market is segmented into Hospitals and Clinics, Cancer Research Institutes and Ambulatory Surgical Centers. Hospitals and clinics dominate the cancer immunotherapy industry since they are the primary healthcare providers who deliver the majority of cancer treatments. These facilities have the infrastructure and resources to provide sophisticated immunotherapy. Furthermore, hospitals and clinics generally employ multidisciplinary teams to provide comprehensive cancer care, including immunotherapy. Their accessibility and skill to manage complex problems make them the favored choice among patients. The huge amount of patient visits and treatments in these settings only strengthens their market domination.

Cancer Immunotherapy Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World
• On the basis of regional analysis, the Global Cancer Immunotherapy Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America leads the cancer immunotherapy market due to its advanced healthcare infrastructure and large expenditure in R&D. The region is home to significant pharmaceutical businesses and research institutions that are at the forefront of immunotherapy innovation. High awareness and early uptake of improved treatments help to establish market dominance. Furthermore, favorable regulatory conditions and significant financing for cancer research contribute to the growth of the immunotherapy market. The presence of a huge patient population seeking advanced cancer medicines reinforces North America's leadership position.

Key Players

• The "Global Cancer Immunotherapy Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are
• Pfizer Inc., AstraZeneca, Merck & Co., Inc., F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Novartis AG, Lilly, Johnson & Johnson Services, Inc., and Immunocore, Ltd.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

• Cancer Immunotherapy Market Recent Developments
• In October 2023, Pfizer launched the MEKTOVI (binimetinib) + BRAFTOVI (encorafenib) for the therapy of adult individuals with advanced non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as identified by an FDA-approved test, was approved from the US Food and Drug Administration (FDA).
• In October 2023, Merck's anti-PD-1 drug KEYTRUDA was authorized by the U.S. Food and Drug Administration (FDA) for the medical care of patients with resectable non-small cell lung cancer (NSCLC) as neoadjuvant therapy and adjuvant treatment following surgery.
• In December 2023, the xU.S. FDA authorized Takeda's FRUZAQLA (fruquintinib) for Formerly Treated Metastatic Colorectal Cancer.

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Cancer Immunotherapy Market, By Therapy Type

• Monoclonal Antibodies
• Checkpoint Inhibitors
• Vaccines against cancer
• Adoptive Cell Transfer
• Others

5.Cancer Immunotherapy Market, By Application

• Solid Tumors
• Hematological Malignancies

6.Cancer Immunotherapy Market, By End-User

• Hospitals and Clinics
• Cancer Research Institutes
• Ambulatory Surgical Centers

7. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

8. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

9. Competitive Landscape

• Key Players
• Market Share Analysis

10. Company Profiles

• Amgen (U.S.)
• AstraZeneca (U.K.)
• F. Hoffmann-La Roche (Switzerland)
• Bayer AG (Germany)
• Bristol-Myers Squibb (U.S.)
• Eli Lilly and Company (U.S.)
• Janssen Global Services, LLC (Belgium)
• Merck (U.S.)
• Novartis (Switzerland)
• Pfizer (U.S.)

11. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

12. Appendix

• List of Abbreviations
• Sources and References